Covid19, Pneumonia, Viral, Pulmonary Function, SARS-CoV Infection
Conditions
Brief summary
Prospective study in a group of patients with COVID-19 pneumonia.
Detailed description
Objective: Assessment of pulmonary and heart dysfunction, fibrosis-related markers and antibodies as well as the search for risk factors for an unfavorable course and possible complications in patients after pneumonia due to SARS-CoV-2 (COVID-19) infection. Patients: A group of approx. 100 patients assessed shortly after pneumonia and followed up, investigated after 3 and 6 months with possible prolongation to 12 months.
Interventions
None listed
Sponsors
Medical University of Warsaw
National Institute for Tuberculosis and Lung Diseases, Poland
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Confirmed SARS-CoV-2 infection with pneumonia hospitalized 2. Two negative PCR results of a swab from the respiratory tract in succession, including the last one taken no later than 3 days before the planned lung function tests (1st visit).
Exclusion criteria
1. Lack of patient consent, 2. Present contraindications for lung function tests 3. Inability to perform correctly lung function measurements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in lung transfer factor for carbon monoxide (TL,CO) at 3, 6 and 12 months after COVID-19 pneumonia | 0, 3, 6, 12 months after COVID-19 pneumonia | Lung transfer factor for carbon monoxide (TL,CO) will be measured using single breath method, results will be reported as absolute values (mmol/min/kPa) |
| Change from baseline in forced vital capacity (FVC) at 3, 6 and 12 months after COVID-19 pneumonia | 0, 3, 6, 12 months after COVID-19 pneumonia | Forced vital capacity (FVC) will be measured using spirometry according to ATS/ERS 2019 guidelines, results will be reported as absolute values (L) |
| Change from baseline in forced expiratory volume at 1 second (FEV1) at 3, 6 and 12 months after COVID-19 pneumonia | 0, 3, 6, 12 months after COVID-19 pneumonia | Forced expiratory volume at 1 second (FEV1) will be measured using spirometry according to ATS/ERS 2019 guidelines, results will be reported as absolute values (L) |
| Change from baseline in total lun capacity (TLC) at 3, 6 and 12 months after COVID-19 pneumonia | 0, 3, 6, 12 months after COVID-19 pneumonia | Total lung capacity will be measured using body plethysmography method according to ATS/ERS 2005 guidelines, results will be reported as absolute values (L) |
| Change in prevalence of abnormal (low) lung transfer factor for carbon monoxide (TL,CO) results at 3, 6 and 12 months after COVID-19 pneumonia | 0, 3, 6, 12 months after COVID-19 pneumonia | Abnormal (low) lung transfer factor for carbon monoxide (TL,CO) will be identified with cut-off point at the level of 5th percentile (-1.64 SD) using most recent predicted values (GLI-2017), prevalence will be reported as % of investigated group |
| Change in prevalence of obstructive ventilatory impairment at 3, 6 and 12 months after COVID-19 pneumonia | 0, 3, 6, 12 months after COVID-19 pneumonia | Obstructive ventilatory impairment (airway obstruction) will be identified with FEV1/FVC ratio below lower limit of normal, cut-off point at the level of 5th percentile (-1.64 SD) will be used with most recent predicted values (GLI-2012), prevalence will be reported as % of investigated group |
| Change in prevalence of restrictive ventilatory impairment at 3, 6 and 12 months after COVID-19 pneumonia | 0, 3, 6, 12 months after COVID-19 pneumonia | Restrictive ventilatory impairment will be identified with total lung capacity (TLC) below lower limit of normal, cut-off point at the level of 5th percentile (-1.64 SD) will be used with most recent predicted values, prevalence will be reported as % of investigated group |
| Change in lung structure from the baseline | 3, 6, 12 months | Change in lung structure will be assessed using high resolution computed tomography (HRCT) performed at 3, 6 and 12 months after initial investigation. Quantitive assessment of abnormalities will be performed and compared with initial investigation performed during acute phase of COVID-19 pneumonia. |
Countries
Poland
Outcome results
None listed